In a society that often treats those living with a disability as "less than," columnist Mary Shaniqua reminds her community ...

BEAM-101, a gene-editing stem cell therapy, showed early signs of efficacy among the first treated sickle cell patients in a ...

An unfortunate reality is that life costs more when you are disabled. Why is this? Simply put, living with a disability often ...

The FDA granted orphan drug status to Kind Pharmaceuticals' investigational oral small molecule AND017 to treat SCD.

Editas Medicine announced proof-of-concept data for a gene-editing approach for sickle cell disease that doesn't need a stem ...

For all of its challenges, living with sickle cell has offered columnist Oluwatosin Adesoye resilience, empathy, support, and happiness.

Although approximately 1 in 6 people worldwide are living with a significant disability, the narrative that those of us with disabilities deserve less continues to be perpetuated. As a sickle cell ...

AB Science said it received a notice of allowance from the European Patent Office for a patent covering the use of the experimental oral therapy masitinib to treat sickle cell disease (SCD). The ...

Enrollment has finished for the Phase 3 RISE UP study, which is testing the oral therapy mitapivat in people with sickle cell ...

Pfizer’s recent decision to withdraw Oxbryta (voxelotor) from global markets feels like a devastating blow for many people with sickle cell disease. Oxbryta’s conditional approval in 2019 by the U.S.